Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin Combined With Lobaplatin in Recurrent or Metastatic Triple-negative Breast Cancer
NCT05546255Phase 2Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Jun 2020
- Primary completion
- Dec 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin, lobaplatin in triple-negative breast cancer (TNBC), sponsored by Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
eribulinlobaplatin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05546255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05546255.